Epidemiology and management of nitroimidazole-refractory giardiasis
Journal of Travel Medicine · 2026
DOI: 10.1093/jtm/taag002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Travel Medicine, 2026. Verfasst von Anna Boté-Casamitjana und 6 weiteren Autor:innen. Beteiligte Einrichtung: Hospital for Tropical Diseases, University College London Hospitals NHS Trust, 235 Euston Road, London NW12BU, United Kingdom. Hauptthemen laut MEDLINE: Giardiasis, Nitroimidazoles, Antiprotozoal Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Giardia is one of the most prevalent gastrointestinal protozoan pathogens globally. Nitroimidazole drugs are usually the first line of treatment, but nitroimidazole-refractory giardiasis (NRG), where infections fail to respond to these agents, is increasingly reported. At our centre, for laboratory-proven refractory giardiasis, a stepwise treatment ladder is used with albendazole plus tinidazole as second-line and mepacrine as third-line therapy.
Methods
We conducted a retrospective review between 2020 and 2024 at the Hospital for Tropical Diseases, London. Laboratory records identified adults and children with Giardia detected by stool microscopy or molecular methods. Treatment details and clinical information were extracted from electronic patient records. NRG and clearance failure were defined as a positive molecular test at least two weeks after completion of treatment.
Results
A total of 531 cases were identified. Of these, 59.0% (N = 311) were diagnosed through screening of high-risk individuals attending clinics for people seeking asylum and refugees (PSAR; Cohort A). The remaining 41.0% (N = 220) were symptomatic patients (Cohort B). In Cohort A, the prevalence of NRG was 36.3% (49/135), with children showing significantly higher odds of clearance failure compared to adults (adjusted OR, 4.81; 95% CI, 1.09–21.40; P = 0.0367). In Cohort B, 34.1% of treatment-naïve travellers had NRG. Travel to India was strongly associated with NRG (adjusted OR, 4.19; 95% CI, 1.72–11.00; P = 0.002). Second-line treatment regimens with albendazole plus tinidazole were effective, and third-line mepacrine therapy was well tolerated with no adverse reactions and successful in nearly all cases.
Conclusions
NRG was common in both asymptomatic and symptomatic individuals, particularly among children seeking asylum and travellers who had visited India. NRG likely results from multiple factors, including protozoal drug resistance and host-related factors. While our current treatment ladder appears effective, further research is needed to understand the mechanisms underlying treatment failure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospital for Tropical Diseases, University College London Hospitals NHS Trust, 235 Euston Road, London NW12BU, United Kingdom.
- Department of Clinical Parasitology, Health Services Laboratories, 1 Mabledon Pl, London WC1H 9AX, United Kingdom.
- Diagnostic Parasitology Laboratory, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, United Kingdom.
- London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, United Kingdom.
- Children and Young People's Division, University College London Hospitals NHS Foundation Trust, 235 Euston Road, London NW12B, United Kingdom.
- Institute of Child Health-Great Ormond Street, University College London, 30 Guilford St, London WC1N 1EH, United Kingdom.
ORCID-Profile: Anna Boté-Casamitjana
Zitieren
APA
Boté-Casamitjana, A., Bodhani, R., Chiodini, P. L., Longley, N., Godbole, G., Eisen, S., & Nabarro, L. E. (2026). Epidemiology and management of nitroimidazole-refractory giardiasis. Journal of Travel Medicine. https://doi.org/10.1093/jtm/taag002
Vancouver
Boté-Casamitjana A, Bodhani R, Chiodini PL, Longley N, Godbole G, Eisen S, et al. Epidemiology and management of nitroimidazole-refractory giardiasis. Journal of Travel Medicine. 2026. doi:10.1093/jtm/taag002
BibTeX
@article{BotCasamitjana2026,
author = {Boté-Casamitjana, Anna and Bodhani, Rashmita and Chiodini, Peter L and Longley, Nicky and Godbole, Gauri and Eisen, Sarah and Nabarro, Laura E},
title = {Epidemiology and management of nitroimidazole-refractory giardiasis},
journal = {Journal of Travel Medicine},
year = {2026},
doi = {10.1093/jtm/taag002}
}
EUVIMED